# Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH

> **NCT07204041** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 40 (estimated)

## Conditions studied

- Langerhans Cell Histiocytosis (LCH)

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Thalidomide (100mg)
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07204041
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-08-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07204041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07204041, "Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07204041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*